Key Highlights
- $31M seed financing led by a16z Bio + Health
- Alchemy to expand in-house pharmacy programs across 20 states
- Focus on serving HIV and Hepatitis C (HCV) patient populations
- Partnerships with FQHCs, STD, and Ryan White clinics
- Alchemy’s platform to enhance patient care and clinic financial impact
Source: Direct
Notable Quotes
- “Investing in Alchemy is deeply personal, not only as a person living with HIV, but because I’ve witnessed firsthand the devastating impacts of HIV in our communities.” — Earvin “Magic” Johnson, Chairman & CEO at Magic Johnson Enterprises
- “I’m convinced that the number one barrier to medication access for HIV patients is the friction that exists in navigating the US pharmacy system.” — Peter Park, Founder and Co-CEO at Alchemy
- “The Alchemy team has a proven track record building for challenging and underserved communities, and we’re looking forward to supporting them.” — Julie Yoo, General Partner at a16z Bio + Health
SoHC's Take
Alchemy’s $31M seed financing represents a significant step toward addressing the critical gaps in pharmacy access for underserved HIV and HCV patient populations. By focusing on in-house pharmacy solutions for Federally Qualified Health Centers (FQHCs), STD, and Ryan White clinics, Alchemy provides an innovative, end-to-end approach that streamlines care and improves outcomes. This round of funding will accelerate the company’s expansion across 20 states, further solidifying its role in transforming the clinic-pharmacy model for vulnerable communities.
